JPC0323

JPC0323, also known as N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)oleamide, is a dual serotonin 5-HT_2C and 5-HT_2A receptor positive allosteric modulator related to oleamide. It showed negligible affinity for roughly 50other targets and did not bind to the orthosteric sites of these receptors. The drug does not affect the serotonin 5-HT_2B receptor.

JPC0323 showed favorable pharmacokinetic properties in preclinical research. It produced hypolocomotion in a serotonin 5-HT_2C receptor-dependent but not serotonin 5-HT_2A receptor-dependent manner in rats, suggesting that it might be a preferential serotonin 5-HT_2C receptor positive allosteric modulator in vivo. The drug was not assessed in terms of head-twitch response, an animal behavioral proxy of psychedelic effects. It is unknown whether it might have hallucinogenic effects via serotonin 5-HT_2A receptor potentiation, but its developers speculated that it might have reduced potential in this regard compared to orthosteric agonists.

JPC0323 was derived as an analogue of the fatty acid amide oleamide and was first described in the scientific literature by 2023. It was described as a "first-in-class" dual serotonin 5-HT_2C and 5-HT_2A receptor positive allosteric modulator.

See also

• 5-HT_2C receptor § Positive allosteric modulators
• 5-HT_2A receptor § Positive allosteric modulators
• AB0124 and CTW0404

References